Efficacy of a new nanoemulsion artificial tear in dry eye disease management: Study protocol for a prospective cohort study
PLOS One · 09.05.2025 · 20 (5) · e0323523
DOI: 10.1371/journal.pone.0323523 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift PLOS One, online erschienen am 09.05.2025. Verfasst von Xulin Liao und 7 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Eye and Vision Research (CEVR), Shatin, Hong Kong SAR, China. Hauptthemen laut MEDLINE: Dry Eye Syndromes, Lubricant Eye Drops, Ophthalmic Solutions. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Alcon Research Investigator Initiated Trial grant.
Abstract (Originalsprache)
Background
Dry eye disease (DED) is a complex ocular disorder with a significant prevalence worldwide, especially in the Asian population. This study aimed to investigate changes in dry eye symptoms and signs following regular use of a new nanoemulsion eye drop, Systane COMPLETE Multi-Dose Preservative-Free (MDPF), in patients with mild to moderate DED in the Asian population. Methods and design This is a prospective cohort study (ClinicalTrials.gov identifier: NCT06188260) that aims to recruit approximately 40 patients from the Asian population suffering from mild to moderate DED. Mild to moderate DED is defined according to the Tear Film and Ocular Surface Society (TFOS) Dry Eye Workshop (DEWS) II diagnostic criteria, including an Ocular Surface Disease Index (OSDI) score between 13–32, and with at least one of the following positive signs: corneal staining, Non-Invasive Tear Breakup Time (NITBUT), or osmolarity. The proposed follow-up period is 3 months. Patients undergo three assessments: baseline before using the eye drops, and follow-up visits after 2 weeks and 3 months regular use of the eye drops (four times daily). The primary outcome is the change in the OSDI score at 2 weeks.
Discussion
The results examine the dry eye symptoms before and after using the new nanoemulsion eye drop, Systane COMPLETE MDPF, in a cohort of mild to moderate DED sufferers. The findings may provide new treatment options for dry eye sufferers with significant clinical implications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Centre for Eye and Vision Research (CEVR), Shatin, Hong Kong SAR, China.
- Centre for Myopia Research, School of Optometry, The Hong Kong Polytechnic University, Kowloon, Hong Kong SAR, China.
- Research Centre for SHARP Vision (RCSV), The Hong Kong Polytechnic University, Kowloon, Hong Kong SAR, China.
- School of Optometry & Vision Science, University of Waterloo, Waterloo, Ontario, Canada.
- Department of Applied Biology and Chemical Technology, The Hong Kong Polytechnic University, Kowloon, Hong Kong SAR, China.
ORCID-Profile: Biyue Guo, Jimmy S H Tse
Förderung
- Alcon Research Investigator Initiated Trial grant
Zitieren
APA
Liao, X., Guo, B., Bian, J., Li, P. H., Tse, J. S. H., Ngo, W., Zhou, L., & Lam, T. (2025). Efficacy of a new nanoemulsion artificial tear in dry eye disease management: Study protocol for a prospective cohort study. PLOS One, 20(5), e0323523. https://doi.org/10.1371/journal.pone.0323523
Vancouver
Liao X, Guo B, Bian J, Li PH, Tse JSH, Ngo W, et al. Efficacy of a new nanoemulsion artificial tear in dry eye disease management: Study protocol for a prospective cohort study. PLOS One. 2025;20(5):e0323523. doi:10.1371/journal.pone.0323523
BibTeX
@article{Liao2025,
author = {Liao, Xulin and Guo, Biyue and Bian, Jingfang and Li, Peter H and Tse, Jimmy S H and Ngo, William and Zhou, Lei and Lam, Thomas},
title = {Efficacy of a new nanoemulsion artificial tear in dry eye disease management: Study protocol for a prospective cohort study},
journal = {PLOS One},
year = {2025},
volume = {20},
number = {5},
pages = {e0323523},
doi = {10.1371/journal.pone.0323523}
}
EUVIMED